Javier Martín-Broto

53PUBLICATIONS
254CO-AUTHORS
Molecular targetsSolid tumoursCancer therapy (excl. chemotherapy and radiation therapy)Regenerative medicine (incl. stem cells)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (53)

|Jun 10, 2026
Brigimadlin Versus Doxorubicin in Advanced Dedifferentiated Liposarcoma: Efficacy, Safety and Translational Data from Brightline-1, a Randomized Phase 2/3 Trial.

|Mar 16, 2026
IMMUNOSARC II Master Trial: Phase II Study of Sunitinib and Nivolumab in Clear Cell Sarcoma Cohort.

Javier Martin-Broto, Sandra J Strauss, Emanuela Palmerini

|Mar 12, 2026
Safety and Efficacy of Epirubicin, Ifosfamide, and Nivolumab as First-Line Treatment for Patients with Undifferentiated Pleomorphic Sarcoma.

Javier Martin-Broto, Javier Martinez-Trufero, Roberto Diaz-Beveridge

|Jan 20, 2026
Gemcitabine plus selinexor in selective advanced sarcomas: a phase I of the Spanish group for research on sarcoma study.

Javier Martin-Broto, Antonio Casado, Gloria Marquina

|Jan 15, 2026
Validation of a Seven-Gene Predictive SIGNature for the Efficacy of Immuno-Oncology PD-1 Inhibitors in Patients with Sarcoma.

David S Moura, Jesus Lopez-Marti, Hussein Tawbi

|Jan 14, 2026
Reply to: Mifamurtide in Nonmetastatic High-Grade Osteosarcoma.

Emanuela Palmerini, Massimo Serra, Toni Ibrahim

Pageof 9

Frequent Collaborators

18 joint publications

Nadia Hindi

16 joint publications

David S Moura

9 joint publications

Jean-Yves Blay

9 joint publications

Javier Martínez-Trufero